A case–control analysis of oral contraceptive use and breast cancer subtypes in the African American Breast Cancer Epidemiology and Risk Consortium

Traci N Bethea¹*, Lynn Rosenberg¹, Chi-Chen Hong², Melissa A Troester³, Kathryn L Lunetta⁴, Elisa V Bandera⁵, Pepper Schedin⁶, Laurence N Kolonel⁷, Andrew F Olshan³, Christine B Ambrosone² and Julie R Palmer¹

Abstract

Introduction: Recent oral contraceptive (OC) use has been consistently associated with increased risk of breast cancer, but evidence on specific breast cancer subtypes is sparse.

Methods: We investigated recency and duration of OC use in relation to molecular subtypes of breast cancer in a pooled analysis of data from the African American Breast Cancer Epidemiology and Risk Consortium. The study included 1,848 women with estrogen receptor-positive (ER+) breast cancer, 1,043 with ER-negative (ER-) breast cancer (including 494 triple negative (TN) tumors, which do not have receptors for estrogen, progesterone, and human epidermal growth factor 2), and 10,044 controls. Multivariable polytomous logistic regression models were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for exposure categories relative to never use, controlling for potential confounding variables.

Results: OC use within the previous 5 years was associated with increased risk of ER+ (OR 1.46, 95% CI 1.18 to 1.81), ER- (OR 1.57, 95% CI 1.22 to 1.43), and TN (OR 1.78, 95% CI 1.25 to 2.53) breast cancer. The risk declined after cessation of use but was apparent for ER+ cancer for 15 to 19 years after cessation and for ER- breast cancer for an even longer interval after cessation. Long duration of use was also associated with increased risk of each subtype, particularly ER-.

Conclusions: Our results suggest that OC use, particularly recent use of long duration, is associated with an increased risk of ER+, ER-, and TN breast cancer in African American women. Research into mechanisms that explain these findings, especially the association with ER- breast cancer, is needed.
in African American women than in women of European ancestry [17-19].

Some risk factors, particularly hormone-related factors, appear to differentially associate with specific breast cancer subtype [20,21], but evidence on OC use in relation to specific breast cancer subtypes is sparse and the findings are inconsistent [22]. Some studies find OC use to be associated with increased risk of ER+ and ER− breast cancer [4,9], others with increased risk of ER− breast cancer only [23], and yet others observe an association solely for ER+ breast cancer [24]. With respect to TN breast cancer, null results [2,25] and an increased risk [23,26] have been observed for OC use.

The objective of the present study was to investigate OC use in relation to molecular subtypes of breast cancer in African American women using data from a large consortium, the African American Breast Cancer Epidemiology and Risk (AMBER) project. In particular, we were able to assess long duration of OC use and recency of use, including intervals as long as 30 years or more since last use.

**Methods**

**Participating studies and data collection**

The AMBER Consortium has been described in detail elsewhere [27]. Its purpose is to provide enough data and samples for informative assessment of genetic and nongenetic factors in relation to breast cancer subtypes in African American women. The AMBER Consortium pools data from two large case–control studies, the Carolina Breast Cancer Study (CBCS) and the Women’s Circle of Health Study (WCHS), and two large cohort studies, the Black Women’s Health Study (BWHS) and the Multiethnic Cohort Study. Owing to missing data on recency of OC use, the Multiethnic Cohort Study was not included in this analysis, whereas data from the BWHS, the CBCS, and the WCHS were included.

The BWHS is a prospective cohort study of 59,000 African American women aged 21 to 69 years at baseline in 1995 [28]. Participants report data on OC use, other risk factors, and incident disease on biennial questionnaires. Questionnaire follow-up is complete for 80% of the baseline cohort through 2011. New diagnoses of cancer are self-reported on the follow-up questionnaires or identified through linkage with state cancer registries [9,27]. For each case, controls were selected from the pool of BWHS participants who had not developed breast cancer at the date of the case’s breast cancer diagnosis (index date). Controls were frequency-matched to cases on 5-year age group, geographic region, and most recent questionnaire completed before the matched case diagnosis. Exposure and covariate data from that questionnaire and preceding questionnaires were used for the analysis.

The CBCS is a population-based case–control study of women aged 20 to 74 years in North Carolina conducted from 1993 through 2001 [29]. Breast cancer cases are identified through the North Carolina Central Cancer Registry. We used data from the first two phases, in which younger and African American cases were oversampled. Cases and controls were sampled using a modification of randomized recruitment. Controls younger than age 65 years were identified from Division of Motor Vehicle lists and controls age 65 years or older were identified from Health Care Financing Administration lists. Controls were frequency-matched to cases on age in 5-year age groups. Exposure and covariate data were collected through in-person interviews with reference to the year before diagnosis (cases) or interview date (controls) [29]. Response rates were 76% for cases and 55% controls for recruitment of invasive breast cancer cases and matched controls, while response rates were 83% for cases and 65% controls for recruitment of in situ breast cancer cases and matched controls [29].

The WCHS is a population-based case–control study of women aged 20 to 75 years that began in New York in 2003 and currently enrolls participants in New Jersey only [30,31]. Breast cancer cases were identified through major hospitals in New York City and through the New Jersey Cancer Registry. Controls were identified through random digit dialing and through community-based recruitment and are frequency matched to cases on age in 5-year age groups [31]. Exposure and covariate data were collected through in-person interviews with reference to the year before diagnosis (cases) or interview date (controls) [30]. Response rates were 78.7% in cases and 48.2% in controls [32].

Each study obtained informed consent from all participants and was approved by the relevant Institutional Review Boards, which are listed in Acknowledgements. Each study prepared a data file that included questionnaire data for a specified set of variables and pathology data from medical records or state cancer registry records. Data were harmonized at the data coordinating center with regular input from each study’s principal investigator and data collection staff.

**Cases**

Incident cases of breast cancer (primary site codes C500 to C506, C508, and C509 in the International Classification of Diseases for Oncology, Third Edition), not including lobular carcinoma in situ (8520/2), phyllodes tumors (9020), or Paget’s disease (8540/3), were confirmed through medical records and state cancer registry records. Immunohistochemistry results were obtained from hospital pathology records and cancer registry data, and were used to classify cases as ER+, ER−, and TN (ER−/PR−/HER2−). ER data were available for 72% of cases and PR
data were available for 69% of cases. Testing for HER2 has become routine more recently; therefore, HER2 data were available for only 49% of cases. There were no statistically significant differences between women with and without known receptor status by age or OC use. The proportion of ER− cases (Table 1) are similar to those observed for African American women in other data sources [34-36].

**Exposure variables**

**Oral contraceptive use**

The main exposures of interest for the present analyses were self-reported recency of OC use (years since last use) and duration of OC use. Women with a total duration of OC use of less than 1 year were considered to be never users. Recency of OC use was categorized as within the previous 5 years, 5 to 9 years ago, 10 to 14 years ago, 15 to 19 years ago, 20 to 24 years ago, 25 to 29 years ago, or ≥30 years ago. Duration of OC use was categorized as 1 to 4 years, 5 to 9 years, 10 to 14 years, or ≥15 years.

**Covariates**

Self-reported data were available on the following covariates: history of breast cancer in a first-degree female relative (mother, sister, or daughter), age at menarche, parity, age at first birth, lifetime duration of breastfeeding, menopausal status, age at menopause, menopausal female hormone use, height, weight, educational attainment, alcohol consumption, and cigarette smoking. For menopausal status, women who were still menstruating exposure variables.

**Table 1 Characteristics of cases and controls in the AMBER Consortium, by included study (BWHS, CBCS, WCHS)**

| Characteristics of breast cancer cases | BWHS | CBCS | WCHS | Total |
|----------------------------------------|------|------|------|-------|
|                                        | Cases | Controls | Cases | Controls | Cases | Controls | Cases | Controls |
| Total                                  | 1,313 | 804 | 774 | 2,891 |
| ER+                                    | 862 (66) | 436 (54) | 550 (71) | 1,848 (64) |
| ER−                                    | 451 (34) | 368 (46) | 224 (29) | 1,043 (36) |
| Triple negative                        | 155 (12) | 210 (26) | 129 (17) | 494 (17) |
| Age at diagnosis                       |      |      |      |       |
| < 40 years                             | 98 (8) | 129 (16) | 87 (11) | 324 (11) |
| 40 to 49 years                         | 385 (29) | 262 (33) | 209 (27) | 856 (30) |
| 50 to 59 years                         | 456 (35) | 190 (24) | 277 (36) | 923 (32) |
| ≥ 60 years                             | 374 (29) | 223 (28) | 191 (23) | 788 (27) |

**Oral contraceptive use among cases and controls**

|                                        | BWHS | CBCS | WCHS | Total |
|----------------------------------------|------|------|------|-------|
|                                        | Cases | Controls | Cases | Controls | Cases | Controls | Cases | Controls |
| Ever use                               |      |      |      |       |
| No                                     | 525 (40) | 3,768 (45) | 392 (49) | 387 (49) | 374 (48) | 477 (49) | 1,291 (45) | 4,632 (46) |
| Yes                                    | 788 (60) | 4,522 (55) | 412 (51) | 398 (51) | 400 (52) | 492 (51) | 1,600 (55) | 5,412 (54) |
| Recency of OC use                      |      |      |      |       |
| < 5 years                              | 182 (14) | 950 (11) | 68 (8) | 52 (7) | 64 (8) | 73 (8) | 314 (11) | 1,075 (11) |
| 5 to 9 years                           | 68 (5) | 464 (6) | 44 (5) | 32 (4) | 36 (5) | 48 (5) | 148 (5) | 544 (5) |
| 10 to 14 years                         | 77 (6) | 499 (6) | 53 (7) | 59 (8) | 39 (5) | 37 (4) | 169 (6) | 595 (6) |
| 15 to 19 years                         | 105 (8) | 620 (7) | 95 (12) | 85 (11) | 45 (6) | 52 (5) | 245 (8) | 757 (8) |
| 20 to 24 years                         | 108 (8) | 692 (8) | 90 (11) | 102 (13) | 47 (6) | 65 (7) | 245 (8) | 859 (9) |
| 25 to 29 years                         | 124 (9) | 653 (8) | 35 (4) | 46 (6) | 55 (7) | 79 (8) | 214 (7) | 778 (8) |
| ≥ 30 years                             | 124 (9) | 644 (8) | 24 (3) | 21 (3) | 108 (14) | 130 (13) | 256 (9) | 795 (8) |
| Duration of OC use                     |      |      |      |       |
| < 5 years                              | 316 (24) | 1,934 (23) | 159 (20) | 174 (22) | 152 (20) | 207 (21) | 627 (22) | 2,315 (23) |
| 5 to 9 years                           | 235 (18) | 1,364 (17) | 125 (16) | 123 (16) | 121 (16) | 142 (15) | 481 (17) | 1,629 (16) |
| 10 to 14 years                         | 178 (14) | 874 (11) | 81 (11) | 61 (8) | 71 (9) | 75 (8) | 330 (11) | 1,010 (10) |
| ≥ 15 years                             | 59 (4) | 350 (4) | 47 (6) | 40 (5) | 56 (7) | 68 (7) | 162 (6) | 458 (5) |

Data presented as n (%). Total percentages may not add up to 100% due to rounding. Excluding women with unknown duration of OC use and unknown ER status. ER status was unknown for 1,151 breast cancer cases: 90 in CBCS, 308 in WCHS, and 753 in BWHS. AMBER, African American Breast Cancer Epidemiology and Risk; BWHS, Black Women’s Health Study; CBCS, Carolina Breast Cancer Study; ER, estrogen receptor; OC, oral contraceptive; WCHS, Women’s Circle of Health Study.
were classified as premenopausal. Women who had experienced a natural menopause or a hysterectomy with bilateral oophorectomy were classified as postmenopausal. Also classified as postmenopausal were women (n = 60) whose periods had stopped due to use of medica
tion, radiation, or chemotherapy for various health conditions other than breast cancer. Women who had a hysterectomy with retention of one or both ovaries were classified as premenopausal if their index age was less than or equal to the age at which 10% of women in their study had reached natural menopause, and as postmenopausal if their index age was greater than or equal to the age at which 90% of women in their study had reached natural menopause; otherwise, these participants were classified as having unknown menopausal status.

Data analysis
Polytomous logistic regression models were used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for the relation of measures of OC use to ER+ and ER– breast cancer risk. For TN breast cancer risk, polytomous models had three outcomes: TN, ER+, and ER–/not TN. We controlled for age (continuous), study (CBCS, WCHS, BWHS), time period of case diagnosis/control index date (1993 to 1998, 1999 to 2005, 2006 to 2013), family history of breast cancer (yes, no), age at menarche (<12, 12 to 13, ≥14 years), parity (0, 1, 2, ≥3 births), age at first birth (<20, 20 to 24, ≥25 years), lactation (never, ever), menopausal status and age at meno
pause (premenopausal, ≤45, 45 to 49, 50 to 54, ≥55 years), female hormone use (0, <5, ≥5 years of use), body mass index (weight in kilograms divided by height in meters squared; <18.5, 18.5 to 24.9, 25.0 to 29.9, 30.0 to 34.9, ≥35 kg/m²), educational attainment (<12, 12, 13 to 15, 16, ≥16 years), alcohol consumption (1, 1 to 6, ≥7 drinks per week), smoking status (0, <10, 10 to 19, ≥20 pack-years), and geographic region (New Jersey, other Northeast, South, Midwest, West). We used the missing indicator method to handle missing data. For menopausal status, 8.8% of women had missing data; for each of the other covariates, fewer than 2% had missing data. To test for trend across categories of OC duration or OC recency, the ordinal variable was treated as a continuous variable in the regression model. Trend tests were carried out among OC users only. To examine potential differences by subtype, we carried out case–case analyses, in which ORs were computed for the relation of OC use to ER–/not ER+ breast cancer. Effect modification was ex-
plorated through stratification by age, menopausal status, body mass index, and parity. Interaction on the multi-
pllicative scale was tested by the likelihood ratio test, com-
paring models with and without multiplicative interaction terms. Analyses were performed using SAS 9.2 statistical software (SAS Institute Inc., Cary, NC, USA).

In addition to the main analyses, which were carried out in pooled data, study-specific ORs were calculated and combined in a random-effects meta-analysis. The Cochran’s Q statistic was used to test for heterogeneity [37]. Meta-analyses were performed using Stata/SE 11.2 statistical software (StataCorp LP, College Station, TX, USA).

Results
Characteristics of cases and controls are presented in Table 1. Among the 2,891 cases, 1,043 (36%) had tumors that were classified as ER+ and 1,848 (64%) were classified as ER– (Table 1). In addition, 494 of the ER– cases were TN breast cancer. The mean age at diagnosis was 52.7, with 11.2% of cases diagnosed before age 40 and 27.3% diagnosed at age 60 or older. OC use was similar across the three participating studies.

Table 2 presents analyses of OC use in relation to ER+ and ER– breast cancer. Ever OC use was positively associated with both ER+ (OR = 1.15, 95% CI = 1.02 to 1.28) and ER– (OR = 1.24, 95% CI = 1.07 to 1.43) breast cancer. There was a significant dose–response association with recency of OC use for both ER+ and ER– breast cancer (P trend <0.01 and P trend =0.05, respectively). The strongest associations were for OC use within the previous 5 years (OR = 1.46, 95% CI = 1.18 to 1.81) for ER+ breast cancer and OR = 1.57, 95% CI = 1.22 to 2.03 for ER– breast cancer). For ER+ breast cancer, the ORs were elevated through 15 to 19 years since last use and the estimate for 15 to 19 years was statistically signifi-
cant (OR = 1.29, 95% CI = 1.04 to 1.58). For ER– breast cancer, the pattern was less consistent; the OR declined to 1.07 (95% CI = 0.83 to 1.37) at 20 to 24 years since last use, but there was a statistically significant elevation at 25 to 29 years since last use (OR = 1.41, 95% CI = 1.09 to 1.81). Risk of ER– cancer increased with increasing duration of OC use, with ORs of 1.43 (95% CI = 1.13 to 1.80) and 1.54 (95% CI = 1.15 to 2.06) for 10 to 14 and ≥15 years duration, respectively. For ER+ breast cancer, the OR for 10 to 14 years duration was elevated (1.35, 95% CI = 1.12 to 1.61) but the estimate for ≥15 years was approximately 1.00. Among recent users, risk increased with increasing duration of OC use for both ER+ and ER– cancer. The OR for ≥10 years of use that continued into the 5 years before diagnosis or index date was 1.65 (95% CI = 1.27 to 2.15) for ER+ cancer and 1.73 (95% CI = 1.26 to 2.37) for ER– cancer. The corresponding estimates for ≥10 years of use that ended at least 20 years previously was 0.88 (95% CI = 0.65 to 1.19) for ER+ cancer and 1.50 (95% CI = 1.03 to 2.17) for ER– cancer.

In a case–case analysis (data not shown), ever use of OCs (OR = 1.09, 95% CI = 0.92 to 1.29) and OC use within the previous 5 years (OR = 1.08, 95% CI = 0.79 to 1.46) were not associated with ER– breast cancer,
relative to ER+ breast cancer. Increased risk of ER– breast cancer was associated with long duration (≥15 years) of OC use relative to ER+ cancer: the OR was 1.51 (95% CI = 1.07 to 2.15).

In an analysis stratified by invasive and in situ breast cancer (data not shown), results for invasive cancer (1,150 ER+ and 629 ER– cases) were similar to the overall findings: the ORs for invasive ER+ cancer were 1.14 (95% CI = 1.00 to 1.31) for ever use, 1.41 (95% CI = 1.10 to 1.81) for use within the previous 5 years, and 0.95 (0.69 to 1.30) for duration of 15 years or more; the corresponding estimates for invasive ER– cancer were 1.36 (95% CI = 1.14 to 1.62), 1.62 (95% CI = 1.20 to 2.20) and 1.59 (1.11 to 2.29), respectively. For in situ cancer, based on 255 ER+ cases, risk of ER+ breast cancer was significantly elevated for recent OC use (OR = 1.66, 95% CI = 1.02 to 2.68), but was not associated with long duration of OC use (OR = 0.95, 95% CI = 0.51 to 1.75). There were too few ER– in situ cases (n = 43) for an informative analysis.

The relation of OC use to risk of TN breast cancer is presented in Table 3. The OR for recent use of OCs

---

**Table 2 Oral contraceptive use in relation to ER+ and ER– breast cancer**

|                                      | Controls (n) | ER+ Cases (n) | OR (95% CI) | ER– Cases (n) | OR (95% CI) |
|--------------------------------------|--------------|---------------|-------------|---------------|-------------|
| Never users                          | 4,632        | 862           | 1.00        | Reference     | 429         | 1.00 Reference |
| Ever users                           | 5,415        | 990           | 1.15        | (1.02 to 1.28) | 615         | 1.24 (1.07 to 1.43) |
| **OC recency**                       |              |               |             |               |             |
| < 5 years                            | 1,075        | 183           | 1.46        | (1.18 to 1.81) | 131         | 1.57 (1.22 to 2.03) |
| 5 to 9 years                         | 544          | 84            | 1.16        | (0.89 to 1.52) | 64          | 1.33 (0.97 to 1.82) |
| 10 to 14 years                       | 595          | 105           | 1.25        | (0.98 to 1.60) | 64          | 1.12 (0.82 to 1.52) |
| 15 to 19 years                       | 757          | 153           | 1.28        | (1.04 to 1.58) | 92          | 1.14 (0.88 to 1.48) |
| 20 to 24 years                       | 859          | 148           | 1.01        | (0.82 to 1.24) | 97          | 1.07 (0.83 to 1.37) |
| 25 to 29 years                       | 781          | 123           | 0.93        | (0.75 to 1.15) | 91          | 1.41 (1.09 to 1.81) |
| ≥ 30 years                           | 795          | 185           | 1.14        | (0.94 to 1.38) | 71          | 1.14 (0.85 to 1.51) |
| **P trend**                          | <0.01        |               |             |               | 0.05        |
| **OC duration**                      |              |               |             |               |             |
| < 5 years                            | 2,315        | 367           | 1.03        | (0.89 to 1.19) | 260         | 1.21 (1.01 to 1.44) |
| 5 to 9 years                         | 1,629        | 321           | 1.25        | (1.07 to 1.46) | 160         | 1.07 (0.87 to 1.32) |
| 10 to 14 years                       | 1,010        | 209           | 1.35        | (1.12 to 1.61) | 121         | 1.43 (1.13 to 1.80) |
| ≥ 15 years                           | 458          | 89            | 0.98        | (0.76 to 1.27) | 73          | 1.54 (1.15 to 2.06) |
| **P trend**                          | 0.13         |               |             |               | 0.05        |

Joint OC exposure (recency and duration)

| Since last use | Duration     | Cases (n) | OR (95% CI) | Cases (n) | OR (95% CI) |
|---------------|--------------|-----------|-------------|-----------|-------------|
| < 5 years     | < 5 years    | 329       | 39          | 1.13      | (0.78 to 1.62) | 30         | 1.20 (0.78 to 1.83) |
|               | 5 to 9 years | 289       | 45          | 1.60      | (1.12 to 2.28) | 33         | 1.67 (1.10 to 2.53) |
|               | ≥ 10 years   | 457       | 99          | 1.65      | (1.27 to 2.15) | 68         | 1.73 (1.26 to 2.37) |
| 5 to 9 years  | < 5 years    | 172       | 22          | 1.21      | (0.75 to 1.94) | 16         | 1.26 (0.72 to 2.21) |
|               | 5 to 9 years | 140       | 30          | 1.62      | (1.05 to 2.52) | 13         | 0.94 (0.51 to 1.74) |
|               | ≥ 10 years   | 232       | 32          | 0.92      | (0.62 to 1.38) | 35         | 1.59 (1.06 to 2.38) |
| 10 to 19 years| < 5 years    | 466       | 66          | 1.09      | (0.82 to 1.47) | 58         | 1.21 (0.87 to 1.67) |
|               | 5 to 9 years | 451       | 87          | 1.33      | (1.02 to 1.73) | 46         | 0.94 (0.66 to 1.33) |
|               | ≥ 10 years   | 435       | 105         | 1.41      | (1.11 to 1.81) | 52         | 1.24 (0.90 to 1.72) |
| ≥ 20 years    | < 5 years    | 1,344     | 238         | 1.02      | (0.86 to 1.20) | 155        | 1.23 (1.00 to 1.51) |
|               | 5 to 9 years | 748       | 157         | 1.13      | (0.92 to 1.38) | 65         | 1.00 (0.75 to 1.33) |
|               | ≥ 10 years   | 340       | 61          | 0.88      | (0.65 to 1.19) | 39         | 1.50 (1.03 to 2.17) |

CI, confidence interval; ER, estrogen receptor; OC, oral contraceptive; OR, odds ratio. ORs adjusted for age, study, time period, geographic region, education, age at menarche, parity, age at first birth, lactation, first-degree family history of breast cancer, menopausal status and age at menopause, duration of female hormone use, body mass index, alcohol consumption, and pack-years of cigarette smoking. P trend does not include never users.
relative to never use was 1.78 (95% CI = 1.25 to 2.53) and risk declined as the interval since last use increased (P trend = 0.05). Risk increased with increasing duration of OC use, with an OR of 1.62 (95% CI = 1.11 to 2.38) for ≥ 15 years of use (P trend = 0.05). Analyses of a joint variable for duration and recency of use indicated that the increased risk associated with at least 10 years of OC use was statistically significant both for use less than 5 years ago (OR = 1.66, 95% CI = 1.06 to 2.00) and use 5 to 9 years ago (OR = 1.79, 95% CI = 1.04 to 3.07).

In analyses stratified by age (<40 years, 40 to 49 years, ≥50 years), recent and long-duration OC use were associated with increased risk of breast cancer in every age group (Table 4). The interaction was not statistically significant for OC recency or duration (P interaction = 0.75 and P interaction = 0.77, respectively).

In analyses stratified by menopausal status (Table 5), ORs were higher in premenopausal women, but there was not a statistically significant interaction (P interaction = 0.16 for recency, P interaction = 0.06 for duration). Breast cancer risk was elevated for recent OC use in both nulliparous and parous women (Table 5): among nulliparous women the OR for OC use within the previous 5 years was 1.37 (95% CI = 0.98 to 1.92), and the corresponding

| Table 3 Oral contraceptive use in relation to triple-negative breast cancera |
|------------------------------|----------------|-----|----------|
|                              | Controls (n) | Cases (n) | OR (95% CI) |
| Never users                  | 4,632        | 213   | 1.00     | Reference |
| Ever users                   | 5,415        | 282   | 1.14     | (0.93 to 1.40) |
| OC recency                   |               |       |          |            |
| < 5 years ago                | 1,075        | 66    | 1.78     | (1.25 to 2.53) |
| 5 to 9 years ago             | 544          | 33    | 1.37     | (0.88 to 2.12) |
| 10 to 14 years ago           | 595          | 37    | 0.99     | (0.63 to 1.56) |
| 15 to 19 years ago           | 757          | 47    | 1.19     | (0.83 to 1.72) |
| 20 to 24 years ago           | 859          | 40    | 0.85     | (0.59 to 1.24) |
| 25 to 29 years ago           | 781          | 40    | 1.26     | (0.87 to 1.81) |
| ≥ 30 years ago               | 795          | 30    | 0.91     | (0.59 to 1.38) |
| P trend                      |              |       | 0.05     |            |
| OC duration                  |               |       |          |            |
| < 5 years                    | 2,315        | 117   | 1.08     | (0.84 to 1.39) |
| 5 to 9 years                 | 1,629        | 73    | 0.99     | (0.74 to 1.34) |
| 10 to 14 years               | 1,010        | 51    | 1.26     | (0.90 to 1.77) |
| ≥ 15 years                   | 458          | 40    | 1.62     | (1.11 to 2.38) |
| P trend                      |              |       | 0.05     |            |
| Joint OC exposure            |               |       |          |            |
| Since last use               |               |       |          |            |
| Duration                     |               |       |          |            |
| < 5 years                    | 329          | 14    | 1.31     | (0.72 to 2.40) |
| 5 to 9 years                 | 289          | 21    | 2.70     | (1.58 to 4.61) |
| ≥ 10 years                   | 457          | 30    | 1.66     | (1.06 to 2.60) |
| 5 to 9 years                 | 172          | 5     | 0.89     | (0.35 to 2.30) |
| ≥ 10 years                   | 140          | 7     | 1.08     | (0.47 to 2.48) |
| 10 to 19 years               | 232          | 19    | 1.79     | (1.04 to 3.07) |
| ≥ 20 years                   | 466          | 26    | 1.12     | (0.70 to 1.79) |
| 5 to 9 years                 | 451          | 21    | 0.87     | (0.53 to 1.45) |
| ≥ 10 years                   | 435          | 27    | 1.36     | (0.87 to 2.11) |
| ≥ 20 years                   | 1,344        | 72    | 1.11     | (0.83 to 1.49) |
| 5 to 9 years                 | 748          | 22    | 0.67     | (0.42 to 1.06) |
| ≥ 10 years                   | 340          | 15    | 1.14     | (0.65 to 2.00) |

CI, confidence interval; OC, oral contraceptive; OR, odds ratio. a ORs adjusted for age, study, time period, geographic region, education, age at menarche, parity, age at first birth, lactation, first-degree family history of breast cancer, menopausal status and age at menopause, duration of female hormone use, body mass index, alcohol consumption, and pack-years of cigarette smoking. P trend does not include never users.
### Table 4 Oral contraceptive use in relation to breast cancer risk, stratified by age

| Age  | Controls (n) | Cases (n) | OR (95% CI) | OR (95% CI) | OR (95% CI) |
|------|--------------|-----------|-------------|-------------|-------------|
|      | Never users  |           |             |             |             |
|      | 351          | 85        | 1.00 Reference |             |             |
|      | Ever users   | 796       | 1.33 (0.97 to 1.81) | 1.18 (0.98 to 1.42) | 1.15 (1.01 to 1.30) |
|      | OC recency   |           |             |             |             |
|      | < 5 years ago| 482       | 1.55 (1.09 to 2.19) | 1.60 (1.23 to 2.07) | 1.50 (0.99 to 2.28) |
|      | 5 to 9 years | 185       | 1.20 (0.77 to 1.86) | 1.18 (0.86 to 1.63) | 0.95 (0.57 to 1.58) |
|      | ≥ 10 years ago| 154    | 1.04 (0.67 to 1.61) | 1.07 (0.88 to 1.31) | 1.14 (1.00 to 1.29) |
|      | P trend      | 0.02      | <0.01       |             | 0.45        |
|      | OC duration  |           |             |             |             |
|      | < 5 years    | 342       | 1.18 (0.81 to 1.70) | 1.12 (0.90 to 1.40) | 1.08 (0.92 to 1.27) |
|      | 5 to 9 years | 239       | 1.40 (0.95 to 2.06) | 1.06 (0.83 to 1.35) | 1.20 (1.00 to 1.44) |
|      | ≥ 10 years   | 215       | 1.48 (0.99 to 2.20) | 1.39 (1.10 to 1.76) | 1.20 (0.99 to 1.45) |
|      | P trend      | 0.17      | 0.11        |             | 0.26        |

CI, confidence interval; OC, oral contraceptive; OR, odds ratio. *ORs adjusted for age, study, time period, geographic region, education, age at menarche, parity, age at first birth, lactation, first-degree family history of breast cancer, menopausal status and age at menopause, duration of female hormone use, body mass index, alcohol consumption, and pack-years of cigarette smoking. P trend does not include never users.
OR for parous women was 1.55 (95% CI = 1.26 to 1.90) \( (P \text{ interaction} = 0.08) \). Long duration of OC use was associated with breast cancer among parous women, but not among nulliparous women (Table 5). The interaction was not significant \( (P = 0.42) \).

Recent and long-duration OC use were associated with larger increases in breast cancer risk among women who were overweight or obese than among women with body mass index <25 kg/m\(^2\) (Table 6). The interaction was significant for recent OC use \( (P \text{ interaction} = 0.04) \), but not for duration of OC use \( (P \text{ interaction} = 0.16) \).

Figure 1 presents study-specific estimates and ORs for recent (within previous 5 years) and long-term (≥10 years) OC use in relation to ER+ and ER− breast cancer computed from a meta-analysis with a random-effects model. The \( P \) value for heterogeneity was 0.57 or greater for all comparisons, indicating no statistically significant heterogeneity.

**Discussion**

Both recent OC use and long duration of OC use were associated with increased risk of breast cancer in this study of African American women. The positive associations were observed for ER+, ER−, and TN breast cancer. ORs were highest for TN breast cancer: women who had used OCs in the past 5 years were estimated to have a 78% increased risk of TN breast cancer and those who had used OCs for at least 15 years had a 62% increase.

While some studies have found no association of recent OC use with overall breast cancer risk [2,3,5,38,39], many others have reported that recent OC users

---

**Table 5 Oral contraceptive use in relation to breast cancer risk, stratified by menopausal status and parity**

|                      | Controls (n) | Cases (n) | OR (95% CI) | Controls (n) | Cases (n) | OR (95% CI) |
|----------------------|--------------|-----------|-------------|--------------|-----------|-------------|
|                      | Premenopausal women |          |             | Postmenopausal women |          |             |
| Never users          | 1,371        | 363       | 1.00        | Reference    | 2,903     | 854         | 1.00        | Reference    |
| Ever users           | 2,667        | 767       | 1.24        | (1.05 to 1.45)| 2,184     | 703         | 1.16        | (1.01 to 1.33)|
| OC recency           |              |           |             |              |           |             |
| < 5 years ago        | 937          | 273       | 1.54        | (1.25 to 1.90)| 90        | 19          | 1.02        | (0.59 to 1.76)|
| 5 to 9 years ago     | 404          | 113       | 1.31        | (1.01 to 1.72)| 99        | 21          | 0.85        | (0.50 to 1.44)|
| ≥ 10 years ago       | 1,324        | 380       | 1.08        | (0.90 to 1.30)| 1,989     | 654         | 1.17        | (1.02 to 1.34)|
| \( P \text{ trend} \)| <0.01        |           |             |              | 0.39      |             |             |             |
| OC duration          |              |           |             |              |           |             |
| < 5 years            | 1,066        | 276       | 1.11        | (0.91 to 1.35)| 992       | 301         | 1.14        | (0.96 to 1.36)|
| 5 to 9 years         | 818          | 217       | 1.14        | (0.92 to 1.41)| 648       | 222         | 1.24        | (1.02 to 1.50)|
| ≥ 10 years           | 782          | 274       | 1.53        | (1.25 to 1.88)| 542       | 175         | 1.09        | (0.88 to 1.34)|
| \( P \text{ trend} \)| <0.01        |           |             |              | 0.83      |             |             |             |

Nulliparous women

|                      | Controls (n) | Cases (n) | OR (95% CI) | Controls (n) | Cases (n) | OR (95% CI) |
|----------------------|--------------|-----------|-------------|--------------|-----------|-------------|
| Never users          | 917          | 244       | 1.00        | Reference    | 3,706     | 1,046       | 1.00        | Reference    |
| Ever users           | 1,230        | 267       | 1.09        | (0.87 to 1.38)| 4,183     | 1,338       | 1.12        | (1.08 to 1.35)|
| OC recency           |              |           |             |              |           |             |
| < 5 years ago        | 406          | 93        | 1.37        | (0.98 to 1.92)| 669       | 211         | 1.55        | (1.26 to 1.90)|
| 5 to 9 years ago     | 160          | 22        | 0.77        | (0.46 to 1.29)| 383       | 126         | 1.39        | (1.08 to 1.77)|
| ≥ 10 years ago       | 663          | 151       | 1.05        | (0.81 to 1.36)| 3,123     | 982         | 1.15        | (1.03 to 1.29)|
| \( P \text{ trend} \)| 0.16         |           |             |              |           |             |
| OC duration          |              |           |             |              |           |             |
| < 5 years            | 438          | 89        | 1.06        | (0.79 to 1.44)| 1,875     | 538         | 1.11        | (0.97 to 1.27)|
| 5 to 9 years         | 361          | 76        | 1.08        | (0.78 to 1.50)| 1,268     | 405         | 1.22        | (1.05 to 1.42)|
| ≥ 10 years           | 431          | 102       | 1.13        | (0.84 to 1.52)| 1,037     | 390         | 1.37        | (1.17 to 1.60)|
| \( P \text{ trend} \)| 0.61         |           |             |              |           |             |

Parous women

|                      | Controls (n) | Cases (n) | OR (95% CI) | Controls (n) | Cases (n) | OR (95% CI) |
|----------------------|--------------|-----------|-------------|--------------|-----------|-------------|
| Never users          | 917          | 244       | 1.00        | Reference    | 3,706     | 1,046       | 1.00        | Reference    |
| Ever users           | 1,230        | 267       | 1.09        | (0.87 to 1.38)| 4,183     | 1,338       | 1.12        | (1.08 to 1.35)|
| OC recency           |              |           |             |              |           |             |
| < 5 years ago        | 406          | 93        | 1.37        | (0.98 to 1.92)| 669       | 211         | 1.55        | (1.26 to 1.90)|
| 5 to 9 years ago     | 160          | 22        | 0.77        | (0.46 to 1.29)| 383       | 126         | 1.39        | (1.08 to 1.77)|
| ≥ 10 years ago       | 663          | 151       | 1.05        | (0.81 to 1.36)| 3,123     | 982         | 1.15        | (1.03 to 1.29)|
| \( P \text{ trend} \)| <0.01        |           |             |              |           |             |
| OC duration          |              |           |             |              |           |             |
| < 5 years            | 438          | 89        | 1.06        | (0.79 to 1.44)| 1,875     | 538         | 1.11        | (0.97 to 1.27)|
| 5 to 9 years         | 361          | 76        | 1.08        | (0.78 to 1.50)| 1,268     | 405         | 1.22        | (1.05 to 1.42)|
| ≥ 10 years           | 431          | 102       | 1.13        | (0.84 to 1.52)| 1,037     | 390         | 1.37        | (1.17 to 1.60)|
| \( P \text{ trend} \)| 0.01         |           |             |              |           |             |

CI, confidence interval; OC, oral contraceptive; OR, odds ratio. *ORs adjusted for age, study, time period, geographic region, education, age at menarche, parity, age at first birth, lactation, first-degree family history of breast cancer, menopausal status and age at menopause, duration of female hormone use, body mass index, alcohol consumption, and pack-years of cigarette smoking, where appropriate. \( P \text{ trend} \) does not include never users. Women who were missing menopausal status \( (n = 1,218) \) were excluded from the analysis that stratified on this variable. Women who were missing parity \( (n = 13) \) were excluded from the analysis that stratified on this variable.
Table 6 Oral contraceptive use in relation to breast cancer risk, stratified by body mass index

| BMI <25.0 kg/m² | BMI 25.0 to 29.9 kg/m² | BMI ≥30.0 kg/m² |
|----------------|------------------------|-----------------|
|                | Controls (n) | Cases (n) | OR (95% CI) | Controls (n) | Cases (n) | OR (95% CI) | Controls (n) | Cases (n) | OR (95% CI) |
| Never users    | 931          | 231       | 1.00 Reference | 1,503     | 387       | 1.00 Reference | 2,096     | 637       | 1.00 Reference |
| Ever users     | 1,371        | 350       | 1.09 (0.88 to 1.35) | 1,746     | 521       | 1.13 (0.95 to 1.35) | 2,211     | 707       | 1.26 (1.09 to 1.45) |
| OC recency     |              |           |               |            |           |               |            |           |               |
| < 5 years ago  | 361          | 87        | 1.22 (0.87 to 1.71) | 320       | 111       | 1.58 (1.16 to 2.14) | 377       | 112       | 1.57 (1.19 to 2.08) |
| 5 to 9 years   | 156          | 32        | 0.87 (0.55 to 1.38) | 175       | 46        | 1.06 (0.71 to 1.58) | 204       | 69        | 1.71 (1.23 to 2.37) |
| ≥10 years ago  | 851          | 230       | 1.09 (0.87 to 1.38) | 1,248     | 363       | 1.09 (0.90 to 1.31) | 1,627     | 518       | 1.17 (1.01 to 1.36) |
| P trend        | 0.17         |           |               | 0.05      |           |               | 0.04      |           |               |
| OC duration    |              |           |               |            |           |               |            |           |               |
| < 5 years      | 566          | 135       | 1.05 (0.80 to 1.37) | 726       | 198       | 1.12 (0.90 to 1.39) | 986       | 278       | 1.09 (0.91 to 1.30) |
| 5 to 9 years   | 408          | 109       | 1.11 (0.83 to 1.49) | 544       | 152       | 1.04 (0.82 to 1.33) | 651       | 213       | 1.34 (1.09 to 1.64) |
| ≥10 years      | 397          | 105       | 1.11 (0.83 to 1.50) | 476       | 171       | 1.27 (1.00 to 1.61) | 571       | 212       | 1.48 (1.20 to 1.82) |
| P trend        | 0.67         |           |               | 0.48      |           |               | <0.01     |           |               |

BMI, body mass index; CI, confidence interval; OC, oral contraceptive; OR, odds ratio. ORs adjusted for age, study, time period, geographic region, education, age at menarche, parity, age at first birth, lactation, first-degree family history of breast cancer, menopausal status and age at menopause, duration of female hormone use, body mass index, alcohol consumption, and pack-years of cigarette smoking. P trend does not include never users.
experience an increase in risk, which has varied from 24% to 60% [1,6,9,11,12,40]. The present findings are similar in magnitude to the previous positive associations. A collaborative analysis of 54 studies concluded that the increased risk of breast cancer associated with OC use disappears by 10 years after last use [1]. In a large case–control study that included African American women, no association was observed for long intervals (≥20 years) since last OC use [2,3]. However, in the present study of African American women, an increased risk was present up to 15 to 19 years after last use for ER+ cancer and after an even longer interval for ER–cancer. Results for duration of use are less consistent in the literature, with some studies reporting no association with long duration [2,3,25,39,41-43] while others observed a positive association [4-13]. In the present study, long duration use appeared to be more strongly associated with ER– cancer than with ER+ cancer.

There are few previous studies of OC use with molecular subtype of breast cancer. Five studies found associations of OC use with both ER+ and ER– breast cancer [4,8-10,12]. One study found an association for only ER+ breast cancer [24] and two found an association for only ER– breast cancer [23,44], while two other studies found no association for either subtype [45,46]. Of the studies that could evaluate TN or basal-like breast cancer, three found a positive association [10,23,26,47] while two others observed no association [2,25].

Combination OCs contain estrogens and progestins and have been found to increase circulating levels of estradiol [48,49]. A potential mechanism for increased risk of breast cancer with recent OC use is through estrogen-induced or progesterone-induced proliferation of breast cancer cells [50,51], which could cause progression of breast cancer. This mechanism may not be applicable for ER– breast cancer. Estrogens may also promote angiogenesis and stromal cell recruitment [52], which would be relevant for both ER+ and ER– breast cancer. OCs may also cause epigenetic changes, such as a decrease in DNA methylation [53]. DNA hypomethylation may be associated with tumor progression and metastasis [54] and represents another potential mechanism for the relation of OC use to breast cancer risk. It has been suggested that tumors regress after cessation of use of menopausal hormone supplements [55,56]. The tumors associated with menopausal hormone use are ER+.

### Figure 1

Results from meta-analysis of oral contraceptive recency and duration in relation to breast cancer subtype. Odds ratios and 95% confidence intervals from the full model by study and from a random-effects meta-analysis for oral contraceptive (OC) recency in relation to ER+ (A) and ER– (B) breast cancer and OC duration in relation to ER+ (C) and ER– (D) breast cancer. BWHS, Black Women’s Health Study; CBCS, Carolina Breast Cancer Study; ER, estrogen receptor; WCHS, Women’s Circle of Health Study.

| A. ER+ breast cancer: OC use within the previous 5 yrs vs. never use |
|-------------------------|-------------------------|
| BWHS                   | 1.48 (1.13-1.93) |
| CBCS                   | 1.31 (0.72-2.38) |
| WCHS                   | 1.35 (0.87-2.10) |
| Overall                | 1.43 (1.15-1.76) |

Phenomenon = 0.90

| B. ER- breast cancer: OC use within the previous 5 yrs vs. never use |
|-------------------------|-------------------------|
| BWHS                   | 1.53 (1.08-2.16) |
| CBCS                   | 1.77 (1.03-3.04) |
| WCHS                   | 1.40 (0.77-2.55) |
| Overall                | 1.56 (1.20-2.02) |

Phenomenon = 0.85

| C. ER+ breast cancer: ≥10 yrs of OC use vs. never use |
|-------------------------|-------------------------|
| BWHS                   | 1.29 (1.04-1.60) |
| CBCS                   | 1.22 (0.80-1.85) |
| WCHS                   | 1.05 (0.76-1.45) |
| Overall                | 1.21 (1.03-1.43) |

Phenomenon = 0.57

| D. ER-breast cancer: ≥10 yrs of OC use vs. never use |
|-------------------------|-------------------------|
| BWHS                   | 1.43 (1.07-1.92) |
| CBCS                   | 1.49 (0.99-2.23) |
| WCHS                   | 1.38 (0.90-2.11) |
| Overall                | 1.43 (1.17-1.76) |

Phenomenon = 0.97
Whether tumor regression occurs after cessation of OC use is unknown, but this mechanism might not explain results for ER– breast cancer.

Few studies have examined potential effect modification of the relation of OC use to breast cancer risk by age [9,23,57]. Of these, some studies have observed a stronger association with risk among younger women than among older women, but this difference has generally not been statistically significant [4,26,58,59]. In a report from the BWHS, age did not significantly modify the association of OC use with breast cancer subtype [9]. In a Washington state case–control study, ORs for OC use were higher among women under age 40, but there was not a significant interaction by age [23]. In a multisite case–control study, ORs for OC use were significantly higher among women under age 35 and age 35 to 44 years, compared with women age 45 years and older [57]. In the present study, ORs were somewhat higher in the youngest age group, but there was not a significant interaction. ORs were also higher among premenopausal women than among postmenopausal women, but, again, the interaction was not statistically significant and there were few recent users among the postmenopausal women. Previous studies have observed associations of OC use with breast cancer risk in both premenopausal and postmenopausal women [8,45].

Differences in risk of breast cancer by age or menopausal status could reflect changes in OC formulations. The estrogen and progestin composition of OCs has varied, with declining doses of hormones and new types of progestin introduced over time [40,60,61]. There is no clear evidence that some formulations carry higher risk than others [5,62-64]. We were not able to evaluate formulation, as we did not have detailed information on OC type used. Thus, we cannot rule out the possibility that associations vary according to OC formulation. However, while younger women are more likely to use newer OC formulations, our findings did not vary significantly by strata of age or birth cohort in the present study. Moreover, estimates were similar across the studies, which were conducted in different time frames ranging from 1993 to present.

The associations of OC use with breast cancer risk in the present study were stronger among overweight and obese women. No previous studies have assessed whether an association of breast cancer risk with recent or long duration of OC use is modified by body mass index. This finding is particularly important given the high prevalence of obesity in African American women [65]. Obesity may alter the pharmacokinetic parameters of OCs, which could prolong exposure to estrogen in obese women due to an increase in the half-life of circulating estradiol, an increase in the rate of OC absorption, or an increase in bioavailability of the chemical compounds in the OCs [66-68].

The present analysis is the largest yet conducted of OC use in relation to specific subtypes of breast cancer among African American women. It allowed for informative assessment of associations within subtype overall and within some strata of interest. However, statistical power in some subanalyses was limited. Numerous important risk factors for breast cancer were controlled in the analyses. While the studies that contributed to the present analyses differed in study design and in population characteristics, a meta-analysis found no significant heterogeneity in the results. In addition, results on other risk factors, including parity and body size, have been similar across the individual studies [8,21,69-72]. Thus, the results are likely to be generalizable to other African American women. A limitation was that the classification by molecular subtype was based on the particular methods used in each pathology laboratory in the large number of hospitals from which the cases were derived. However, it is unlikely that misclassification will have been related to the OC use of cases. We did not have data to validate self-reported OC use, but validation studies have shown that OC use is generally well reported [5,73,74]. We did not have detailed information on OC type used, and therefore cannot rule out variations in associations by OC formulation.

Conclusions
In sum, our findings suggest that recent OC use, particularly of long duration, is associated with increased risk of ER+, ER–, and TN breast cancer in African American women, with possibly a stronger relation with TN breast cancer. Increases in risk associated with OC use were apparent for up to 15 years or more after cessation of use. The association with OC use was most pronounced among overweight and obese women. Research is needed to investigate the mechanisms by which obesity may further increase the breast cancer risk associated with OC use.

Abbreviations
AMBER: African American Breast Cancer Epidemiology and Risk; BWHS: Black Women’s Health Study; CBCS: Carolina Breast Cancer Study; CI: confidence interval; ER: estrogen receptor; HER2: human epidermal growth factor receptor 2; OC: oral contraceptive; OR: odds ratio; PR: progesterone receptor; TN: triple negative; WCHS: Women’s Circle of Health Study.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
TNB performed the statistical analyses and drafted the manuscript. LR, C-CH, MAT, KLL, EVB, PS, LNK, AFO, and JRP participated in data analysis and interpretation and provided critical feedback. CBA and JRP conceived of the study and participated in the design and coordination of the study. All authors read and approved the final manuscript.

Acknowledgements
The authors would like to thank the contributing studies’ participants and staff. They would also like to acknowledge the late Robert Millikan, DVM.
June 2014 Accepted: 10 February 2015

Author details
1 Stone Epidemiology Center at Boston University, 1010 Commonwealth Avenue, Boston, MA 02215-1201, USA. 2 Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY 14263, USA. 3 Department of Epidemiology, University of North Carolina at Chapel Hill, 135 Dauer Drive, McGavran-Greenhill Hall, Campus Box #7435, Chapel Hill, NC 27599, USA. 4 Department of Biostatistics, Boston University School of Public Health, Crosstown Center, 801 Massachusetts Avenue, 3rd Floor, Boston, MA 02118, USA. 5 Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08903, USA. 6 Department of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Rm RJH 5181 Richard Jones Hall/Mail Code L215, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA. 7 Cancer Epidemiology Program, University of Hawaii Cancer Center, 701 Iliahi Street, Honolulu, HI 96813, USA.

Received: 29 July 2014
Published online: 21 February 2015

References
1. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet. 1996;347:1713–27.
2. Ma H, Wang Y, Sullivan-Halley J, Weiss L, Marchbanks PA, Spirtas R, et al. Use of four biomarkers to evaluate the risk of breast cancer subtypes in the women's contraceptive and reproductive experiences study. Cancer Res. 2010;70:755–67.
3. Marchbanks PA, McDonald JA, Wilson HG, Folger SG, Mandel MG, Daling JR, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med. 2002;346:2025–32.
4. Rosenberg L, Zhang Y, Coogan PF, Strom BL, Palmer JR. A case–control study of oral contraceptive use and incident breast cancer. Am J Epidemiol. 2009;169:473–9.
5. Hunter DJ, Colditz GA, Hankinson SE, Malpezi S, Spiegelman D, Chen W, et al. Oral contraceptive use and breast cancer: a prospective study of young women. Cancer Epidemiol Biomarkers Prev. 2010;19:2496–502.
6. Urban M, Banks E, Egger S, Canfell K, O'Connell D, Brinton LA, Madigan MP, Sherman ME. Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev. 2004;13:155B–68.
7. Dolle JM, Daling JR, White E, Brinton LA, Doody DR, Porter PL, et al. Risk factors for triple-negative breast cancer in women under the age of 45 years. Cancer Epidemiol Biomarkers Prev. 2009;18:1157–66.
8. Rette R, Tikk K, Lukanova A, Tjonneland A, Olsen A, Overvad K, et al. Reproductive factors and risk of hormone receptor positive and negative breast cancer: a cohort study. BMC Cancer. 2013;13:584.
9. Phipps AJ, Chlebowski RT, Frentzel B, Terry M, Wactawski-Wende J, Kuller LH, et al. Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inst. 2011;103:470–7.
10. Gaedt MW, Press MF, Haile RW, Lynch CF, Glaser SL, Schildkraut J, et al. Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger. Breast Cancer Res Treat. 2011;130:867–77.
11. Palmer JR, Ambrosone CB, Olshan AF. A collaborative study of the etiology of breast cancer subtypes in African American women: the AMBER consortium. Cancer Causes Control. 2010;21:329–39.
12. Rosenberg L, Adams-Campbell LL, Palmer JR. The Black Women's Health Study: a follow-up study for causes and prevention of illness. J Am Med Womans Assoc. 1995;50:56–8.
13. Millikan RC, Neuman B, Tse CK, Moorman PG, Conway K, Dresler LG, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 2008;109:123–39.
14. Ambrosone CB, Ciupak GL, Bandera EV, Jandorf L, Boesjberg MH, Zirpoli V, et al. Conducting molecular epidemiological research in the Age of HIPAA: a multi-institutional case-control study of breast cancer in African-American and European-American women. J Oncol. 2009;2009:71250.
15. Bandera EV, Chandran U, Zirpoli G, McCann SE, Ciupak G, Ambrosone CB. Rethinking sources of representative controls for the conduct of case–control studies in minority populations. BMC Med Res Methods. 2013;13:71.
32. Chandran U, Zirpoli G, Cuapak G, McCann SE, Gong Z, Pawlish K, et al. Racial disparities in red meat and poultry intake and breast cancer risk. Cancer Causes Control. 2013;24:2127–29.
33. International Classification of Diseases for Oncology (ICD-O). Fritz A, Percy C, Jack A, Shanmugasanthiram K, Sobin L, Parkin DM, Whelan S. (Eds.). Third Edition, First Revision. World Health Organization, Geneva, Switzerland; 2013.
34. Gasparrini S, Dupuis J, Garm P, Collia S, Winchester DP. Hormone receptor status of breast tumors in black, Hispanic, and non-Hispanic white women. An analysis of 13,239 cases. Cancer. 1996;77:1465–71.
35. Parise CA, Bauer RR, Caggiano V. Variation in breast cancer subtypes with age and race/ethnicity. Crit Rev Oncol Hematol. 2010;76:44–52.
36. Iversen A, Thune I, McTiernan A, Emaus A, Finstad SE, Flote V, et al. Ovarian activity. Contraception. 2009;80:119.
37. Campesi I, Sanna M, Zinellu A, Carru C, Rubattu L, Bulzomi P, et al. Breast Cancer Research. 2013;15:137.
38. Turktoz FP, Solak M, Petekkaya I, Keskin O, Kertmen N, Sarici F, et al. Association between common risk factors and molecular subtypes in breast cancer patients. Breast. 2013;22:344–50.
39. Ursin G, Ross RK, Sullivan-Halley J, Hanisch R, Henderson B, Bernstein L. Use of oral contraceptives and risk of breast cancer in young women. Breast Cancer Res Treat. 1998;50:175–84.
40. Cogliano V, Grosse Y, Baan R, Straif K, Secretan B, El Ghissassi F. Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. Lancet. 2005;366:553–5.
41. Rosenblatt KA, Gao DL, Ray RM, Nelson ZC, Wernli KJ, Li W, et al. Oral contraceptives and the risk of all cancers combined and site-specific cancers in Shanghai. Cancer Causes Control. 2009;20:27–34.
42. Hannaford PC, Selvaraj S, Elliott AM, Angus V, Iversen L, Lee AJ. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner’s oral contraception study. BMJ. 2007;335:651.
43. Hankinson SE, Colditz GA, Manson JE, Willett WC, Hunter DJ, Stampfer MJ, et al. A prospective study of oral contraceptive use and risk of breast cancer (Nurses’ Health Study, United States). Cancer Causes Control. 1997;8:65–72.
44. Ma H, Bernstein L, Ross RK, Ursin G. Hormone-related risk factors for breast cancer in women under age 50 years by estrogen and progesterone receptor status: results from a case–control and a case–control comparison. Breast Cancer Res. 2008;9:R99.
45. Cotterchio M, Keigler N, Thies B, Sloan M, Bahl S. Hormonal factors and the risk of breast cancer according to estrogen- and progesterone-receptor subgroup. Cancer Epidemiol Biomarkers Prev. 2003;12:1053–60.
46. Bao PP, Shu XO, Gao YT, Zheng Y, Cai H, Deming SL, et al. Association of dietary factors with breast cancer risk in women 20 to 49 years of age. Cancer Res. 2014;74:4078–89.
47. Marchbanks PA, Curtis KM, Mandel MG, Wilson HG, Jeng G, Folger SG, et al. Oral contraceptive formulation and risk of breast cancer. Contraception. 2012;85:342–50.
48. Bao PP, Shu XO, Gao YT, Zheng Y, Cai H, Deming SL, et al. Association of dietary factors with breast cancer risk in women 20 to 49 years of age. Cancer Res. 2014;74:4078–89.
49. Edelman AB, Cherala G, Munar MY, Dubois B, McNichin M, Stanczyk FZ, et al. Prolonged monitoring of estradiol and levonorgestrel levels confirms an altered pharmacokinetic profile in obese oral contraceptives users. Contraception. 2013;87:220–6.
50. Edelman AB, Carlson NE, Cherala G, Munar MY, Stouffer RL, Cameron JL, et al. Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic–pituitary–ovarian activity. Contraception. 2009;80:119–27.
51. Edelman AB, Cherala G, Stanczyk FZ. Metabolism and pharmacokinetics of contraceptive steroids in obese women: a review. Contraception. 2010;82:194–23.
52. Ambrosone CB, Zirpoli G, Ruszyczyk M, Shankar J, Hong CC, McIvor D, et al. Breast cancer in African-American women: differential effects on breast cancer risk by estrogen receptor status in the Women’s Circle of Health Study. Cancer Causes Control. 2014;25:259–65.
53. Bandera EV, Chandran U, Zirpoli G, Gong Z, McCann SE, Hong CC, et al. Body fatness and breast cancer risk in women of African ancestry. BMC Cancer. 2012;12:274.
54. Bandera EV, Chandran U, Zirpoli G, Gong Z, McCann SE, Hong CC, et al. Body fatness and breast cancer risk in women of African ancestry. BMC Cancer. 2012;12:274.
55. Edelman AB, Carlson NE, Cherala G, Munar MY, Stouffer RL, Cameron JL, et al. Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic–pituitary–ovarian activity. Contraception. 2009;80:119–27.
56. Edelman AB, Cherala G, Stanczyk FZ. Metabolism and pharmacokinetics of contraceptive steroids in obese women: a review. Contraception. 2010;82:194–23.
57. Ambrosone CB, Zirpoli G, Ruszyczyk M, Shankar J, Hong CC, McIvor D, et al. Breast cancer in African-American women: differential effects on breast cancer risk by estrogen receptor status in the Women’s Circle of Health Study. Cancer Causes Control. 2014;25:259–65.
58. Bandera EV, Chandran U, Zirpoli G, Gong Z, McCann SE, Hong CC, et al. Body fatness and breast cancer risk in women of African ancestry. BMC Cancer. 2012;12:274.
59. Bandera EV, Chandran U, Zirpoli G, Gong Z, McCann SE, Hong CC, et al. Body fatness and breast cancer risk in women of African ancestry. BMC Cancer. 2012;12:274.